- Visibility 261 Views
- Downloads 19 Downloads
- DOI 10.18231/j.ijmmtd.2024.040
-
CrossMark
- Citation
Candidemia in a tertiary care hospital: Changing trends
Introduction
Candida species are normal inhabitants of skin and mucosa.[1] It can become pathogenic in situations where the host defences are disturbed. Risk factors include immunocompromised conditions like diabetes mellitus, prolonged use of steroids, long term use of antibiotics, old age, presence of indwelling devices and recent gastrointestinal surgery[1], [2] Candida can cause various clinical manifestations like oropharyngeal candidiasis, vulvovaginal candidiasis, genitourinary candidiasis and blood stream infections.[3] Over the past two decades, blood stream infections (BSI) caused by Candida species are increasing. Prevalence of candidemia in India (2020) ranges from 1.31%- 3.41%.[4], [5] Although Candida albicans was considered as the most common species causing candidemia, BSI caused by Non-albicans Candida(NAC) species like C. tropicalis & C. parapsilosis (in developing countries) and C. glabrata (in developed nations)are emerging as a major cause of nosocomial infections.[5], [6] Increased morbidity and prolonged hospital stay are associated with invasive candidiasis resulting in mortality. Mortality associated with candidemia is estimated to be 19–24% by CDC.[7]
Fluconazole is the most commonly used antifungal for the treatment of candidemia. Candida krusei is intrinically resistant to fluconazole. Other NAC species like, Candida guilliermondii, C.glabrata C. inconspicua are less susceptible to azoles. Though resistance to echinocandins is considered rare, it is also on the rise. Intrinsic and acquired resistance to various antifungals is becoming a major problem in treatment of candidemia.[2] Therefore it is important to identify the Candida species causing sepsis and determine their antifungal susceptibility pattern to select the right antifungal giving appropriate coverage. This will help in effective management of these patients, thus reducing mortality caused by Candida and also to control outbreaks.[8] This study was undertaken to find out prevalence of candida species causing sepsis and its outcome in a tertiary care hospital.
Materials and Methods
Study design
Descriptive cross-sectional study.
Study period
July 2021 to June 2023.
Place of study
Department of Microbiology, tertiary care hospital, Pune
Methodology
All the blood samples received during the study period and which grew Candida species were included in the study. Blood cultures which grew organisms other than Candida species were excluded from the study. Blood samples of patients with suspected candidemia were received in automated blood culture bottles (BD BACTECFX 40) and were incubated in the automated BD BACTEC TM FX (Becton, Dickinson and Company, NJ, and USA). Once the bottle flagged positive, Gram stain was done and presence of gram positive budding yeast cells was recorded. Gram’s staining findings were immediately communicated to clinician for early start of antifungal therapy. Candida species were identified by routine conventional methods like growth on blood agar ([Figure 1]), SDA (Sabouraud Dextrose Agar), germ tube test, CHROM agar Candida (HiMedia, Mumbai, India) ([Figure 2]) and automated identification system (VITEK 2 compact - BioMérieux, France). In vitro antifungal susceptibility profile was determined by the automated antifungal susceptibility system (VITEK 2 BioMérieux, France). Demographic and clinical details of the patients were collected.
Statistical analysis
The collected data was entered in Microsoft excel sheet and analysed. Data presented as numbers and percentages.
Results
A total of 4367 blood cultures were received during the study period. Of this, 131(2.99%) grew Candida species. 36 (out of the 131) isolates were obtained from children below one year of age ([Table 1]). Majority {91 of 131 (69.4%)} of the patients were admitted in critical care units (ICUs) ([Figure 3]), out of which (45) 34.35% were adults, while (46)35.1% were children below 10 years. Male and female patients were equally affected. Majority of the patients had associated co-morbidities like diabetes mellitus, malignancy, chronic kidney disease ([Table 2]). C. parapsilosis was isolated from 42 samples (32%), followed by C. tropicalis 38 (29%) , C. albicans 30 (22.9%), C.guilliermondi 07 (5.34%), C.glabrata 06 (4.58%), C.krusei 05 (3.8) and C.lusitaniae 01 (0.78) ([Figure 4]). Antifungal susceptibility pattern of the Candida isolates showed that 73.2% were susceptible to fluconazole, 88.5% to voriconazole, 90% to caspofungin, 92.3% to micafungin, 81.6% to amphotericin B and 100% to flucytosine ([Figure 5]). A total of 16.6% of C.parapsilosis strains were resistant to fluconazole, voriconazole and amphotericin B while 7.4% were resistant to caspofungin and micafungin. Seventeen (44.7%) C.tropicalis strains were resistant to fluconazole, 7 (18.4%) were resistant to amphotericin B and voriconazole while 4(10.5% ) were resistant to caspofungin and micafungin each. C.albicans strains were fully susceptible to all antifungal agents except (n=4)13.3% of strains which were resistant to fluconazole ([Table 3]) Antifungal susceptibility testing of Candida auris isolates could not be performed.
Follow up
Twenty two (16.79%) patients succumbed to candidemia ([Table 4]). All others responded to azole group of drugs. Two patients infected with Candida auris were treated with echinocandins. Contact precautions were followed while handling these patients.


Age group (in years) |
Number of patients |
0-1 |
36 |
1-10 |
09 |
11-20 |
08 |
21-30 |
07 |
31-40 |
13 |
41-50 |
30 |
51-60 |
15 |
61-70 |
07 |
71-80 |
06 |
>80 |
0 |
Total |
131 |

Co-morbidities associated |
Number of patients with risk factors |
Diabetes mellitus |
40 |
Chronic kidney disease |
20 |
Malignancy |
25 |
Prolonged use of broad spectrum antibiotic |
90 |
Prolonged stay in ICU/NICU ( >1 month) |
30 |
Total parenteral nutrition |
20 |
Premature neonates with respiratory distress |
25 |
Presence of CVC |
28 |


Candida species |
Fluconazole |
Voriconazole |
Caspofungin |
Micafungin |
Amphotericin B |
C. albicans |
4 |
0 |
0 |
0 |
0 |
C. parapsilosis |
7 |
7 |
3 |
3 |
7 |
C. tropicalis |
17 |
7 |
4 |
4 |
7 |
C. guilliermondi |
3 |
1 |
2 |
2 |
2 |
C. krusei |
5IR |
0 |
0 |
0 |
5 |
C.glabrata |
4 |
0 |
4 |
1 |
3 |
C. lusitaniae |
0 |
0 |
0 |
0 |
0 |
Candida species isolated |
Number of patients |
C. parapsilosis |
9 |
C.tropicalis |
7 |
C.glabrata |
4 |
C.albicans |
1 |
C.guilliermondii |
1 |
Discussion
Over the recent years, Candida has emerged as a major cause of blood stream infections. In the United States, Candida species have been found to be the fourth most common cause of blood stream infections.[9] Candida ranks among the top ten pathogens responsible for hospital acquired blood stream infections.[2] A study by Chakrabarti A has found that the rate of candidemia in developing countries is 4-15 times more than in developed countries.[10] The prevalence of candidemia was found to be 2.99 % in our study. The prevalence of candidemia was found to be 3.4% by Ahmed S et al in Uttar Pradesh, 1.3% by Kaur H et al in Chandigarh (North India), 1.4% by Jain V et al in Rajasthan (Western India), 3.8% by Behera C et al in Bhubaneswar (Eastern India) and 0.65% by Giri S et al in Tamil Nadu (South India).[4], [5], [11], [12], [13] In our study, 27.4% of the population was below 1 year of age. As per Mantadakis E et al, candidemia is several times more common in infants and neonates than in adults .Main risk factors associated with candidemia in children were respiratory diseases, prematurity, ICU admission, mechanical ventilation, neutropenia, and malignancy. [14] In our study comorbidities associated with candidemia in neonates were prematurity and respiratory distress syndrome. All the children were admitted in critical care units. In the present study the risk factors in adults were diabetes mellitus, chronic kidney disease and malignancy. In the study of Blyth et al., renal disease, recent surgery, diabetes mellitus and haemodialysis were the frequent risk factors in adults.[15] Underlying conditions like renal insufficiency, trauma, gastrointestinal perforation, prolonged use of broad spectrum antibiotics, stay in ICU or use of central venous catheter were predisposing factors in a study done by Capoor MR et al. [16] It has been observed that candidemia is more common in diabetic patients because of the adhesion of yeast to host epithelium, high serum glucose levels as compared to healthy individuals, poor candidacidal activity of neutrophils and microvascular degeneration. [17] In present study, 19.0% (25) had history of malignancy. Presence of central venous catheter or parenteral nutrition were the reason for development of candidemia in patients with hematologic malignancies in a study by Girmenia C et al.[18]
In India, a change in trend of species causing candidemia in the recent years from C albicans to NAC [6] has been observed. Along with C albicans, other NAC species like C. parapsilosis, C.krusei, C. tropicalis and C. glabrata contribute to 92% of cases candidemia globally. Candida glabrata is common in elderly patients and Candida albicans is more common in children upto 18 years of age. [19] Candida auris which was considered a rare pathogen previously is also becoming a prominent pathogen. [20] This shift could be due to better detection rate of NAC or as a result of rampant use of fluconazole for treatment of all fungal infections resulting in shift in the colonisation and infection with fluconazole resistant strains like C. krusei. [21], [22], [23], [24], [25], [26], [27], [28] In our study, Candida parapsilosis was the commonest species (32%) which correlated with the studies undertaken by Shivprakash et al (28.8%) and Capoor et al. (27.4%).[6], [16] Low prevalence of C. parapsilosis was reported in studies conducted by Sridharan et al (17%) and Bhattacharje et al (17%) and Amir et al (8%).[28], [22], [27]
Fluconazole is the preferred antifungal for treatment of less severe infections while echinocandins are preferred for moderate to severe infections or in systemic candidiasis as per the guidelines from the Infectious Diseases Society of America. [2] Fluconazole being the most frequently used antifungal, its resistance is on the rise in many parts of the world. [4] Various studies have reported resistance to fluconazole i.e 10% by Seyoum E et al in Ethiopia(2020),15% by Bilal H et al in China (2022), 5% by Bedini A et al in Italy(2006) and 34.8% by Bhattacharjee P et al in India(2016).[21], [22], [23], [24] In the present study 26.7% of the isolates were resistant to fluconazole. This is slightly higher than other studies as candidemia caused by NAC was more common in this study. Many species of candida are intrinsically resistant to many antifungals. C. auris is intrinsically resistant to polyenes and fluconazole while C. krusei is intrinsically resistant to fluconazole. Empiric antifungal therapy is usually given in febrile neutropenia patients who do not respond to antibiotic therapy and in cases of perforated peritonitis. This has led to the development of acquired resistance to many antifungals especially the azoles. Mechanisms by which azoles develop resistance are over expression of membrane transporters, alteration of ergosterol biosynthesis, sterol import alteration and genome plasticity. [25]
Hand hygiene, isolation of patient, environmental disinfection and avoiding unnecessary use of broad spectrum antibiotics are measures by which candidemia can be controlled to an extent. If the patient is on central venous catheter, it must be regularly monitored for signs of infection. [26]
Conclusion
The prevalence of candidemia was found to be 2.99%, with an increasing trend of bloodstream infections caused by non-albicans Candida (NAC) species. Most cases occurred in patients admitted in critical care units. Commonly isolated species were Candida parapsilosis and Candida tropicalis, many of which showed resistance to the commonly used antifungal fluconazole. The recent emergence of Candida auris has further complicated the treatment of candidemia. Rapid diagnosis, early treatment, strict infection control measures, and robust antimicrobial stewardship practices are essential to reduce the burden of candidemia.
Ethical Approval
This study was approved by the institutional Ethical Committee (Approval number-BVDUMC/IEC/263).
Conflict of Interest
None.
Source of Funding
None.
References
- V Mohandas, M Ballal. Distribution of Candida species in different clinical samples and their virulence: biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in southern India. J Glob Infect Dis 2011. [Google Scholar]
- M Sanguinetti, B Posteraro. Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 2015. [Google Scholar]
- TE Zaoutis, J Argon, J Chu, JA Berlin, TJ Walsh, C Feudtner. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005. [Google Scholar]
- S Ahmed, M Shahid, N Fatima, F Khan, U Tayyaba. Candidemia – Changing Trends from Candida albicans to Non-Albicans Candida from a Tertiary Care Center in Western UP, India. CHRISMED J Health Res 2020. [Google Scholar]
- H Kaur, S Singh, S M Rudramurthy, A K Ghosh, M Jayashree, Y Narayana. Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility. Indian J Med Microbiol 2020. [Google Scholar]
- S Shivaprakasha, K Radhakrishnan, P M Karim. Candida spp. other than Candida albicans: a major cause of fungaemia in a tertiary care centre. Indian J Med Microbiol 2007. [Google Scholar]
- J Morgan, MI Meltzer, BD Plikaytis, AN Sofair, S Huie-White, S Wilcox. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hospital Epidemiol 2005. [Google Scholar]
- K Montes, B Ortiz, C Galindo, I Figueroa, S Braham, G Fontecha. Identification of Candida Species from Clinical Samples in a Honduran Tertiary Hospital. Pathogens 2019. [Google Scholar] [Crossref]
- M Morrell, VJ Fraser, MH Kollef. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005. [Google Scholar]
- A Chakrabarti. . Fungal Infections in Asia: Eastern Frontier of Mycology 2014. [Google Scholar]
- V Jain, T Nare, K Vishwakarma, A Kundu, A Radhkrishnan, V Tak. P049 Candidemia: Isolate profiling and antifungal susceptibility testing experience from Jodhpur, Western India. Med Mycol 2022. [Google Scholar] [Crossref]
- C Behera, R Mishra, PK Jena, S Mishra, B Sahoo, SB Patnaik. Candidemia in the pediatric intensive care unit in Eastern India. J Pediatr Crit Care 2020. [Google Scholar]
- S Giri, AJ Kindo, J Kalyani. Candidemia in intensive care unit patients: A one year study from a tertiary care center in South India. J Postgrad Med 2013. [Google Scholar]
- E Mantadakis, ZD Pana, T Zaoutis. Candidemia in children: Epidemiology, prevention and management. Mycoses 2018. [Google Scholar]
- CC Blyth, SC Chen, MA Slavin. Not just little adults: candidemia epidemiology,molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009. [Google Scholar]
- MR Capoor, D Nair, M Deb, PK Verma, L Srivastava, P Aggarwal. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis 2005. [Google Scholar]
- C F Rodrigues, M E Rodrigues, M Henriques, Candida. Infections in Patients with Diabetes Mellitus. J Clin Med 2019. [Google Scholar]
- C Girmenia, P Martino, F De Bernardis, G Gentile, M Boccanera, M Monaco, Antonucci. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996. [Google Scholar]
- J Guinea. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 1920. [Google Scholar]
- PG Pappas, MS Lionakis, MC Arendrup, L Ostrosky-Zeichner, BJ Kullberg. Invasive candidiasis. Nat Rev Dis Primers 2018. [Google Scholar] [Crossref]
- E Seyoum, A Bitew, A Mihret. Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia. BMC Infect Dis 2020. [Google Scholar] [Crossref]
- P Bhattacharjee. Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital. Curr Med Mycol 2016. [Google Scholar]
- H Bilal, B Hou, M Shafiq, X Chen, MA Shahid, Y Zeng. Antifungal susceptibility pattern of Candida isolated from cutaneous candidiasis patients in eastern Guangdong region: A retrospective study of the past 10 years. Front Microbiol 2022. [Google Scholar] [Crossref]
- A Bedini, C Venturelli, C Mussini, G Guaraldi, M Codeluppi, V Borghi. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006. [Google Scholar]
- S Bhattacharya, S Sae-Tia, B C Fries. Candidiasis and Mechanisms of Antifungal Resistance. Antibiotics (Basel) 2009. [Google Scholar] [Crossref]
- GM Snyder, SB Wright. The Epidemiology and Prevention of Candida auris. Curr Infect Dis Rep 2019. [Google Scholar] [Crossref]
- A Arastehfar, S Yazdanpanah, M Bakhtiari, W Fang, W Pan, S Mahmoudi. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018) Get access Arrow. Med Mycol 2016. [Google Scholar]
- S Sridharan, R Gopalakrishnan, P S Nambi, S Kumar, N Sethuraman, V Ramasubramanian. Clinical Profile of Non-neutropenic Patients with Invasive Candidiasis: A Retrospective Study in a Tertiary Care Center. Indian J Crit Care Med 2021. [Google Scholar]
How to Cite This Article
Vancouver
Kshirsagar D, Thakar VH, Dalal BA, Babu A, Modak M, Kumar M. Candidemia in a tertiary care hospital: Changing trends [Internet]. IP Int J Med Microbiol Trop Dis. 2025 [cited 2025 Sep 07];10(3):230-235. Available from: https://doi.org/10.18231/j.ijmmtd.2024.040
APA
Kshirsagar, D., Thakar, V. H., Dalal, B. A., Babu, A., Modak, M., Kumar, M. (2025). Candidemia in a tertiary care hospital: Changing trends. IP Int J Med Microbiol Trop Dis, 10(3), 230-235. https://doi.org/10.18231/j.ijmmtd.2024.040
MLA
Kshirsagar, Devashree, Thakar, Vrushali Harsh, Dalal, Bharati Avinash, Babu, Aishwarya, Modak, Meera, Kumar, Mahadevan. "Candidemia in a tertiary care hospital: Changing trends." IP Int J Med Microbiol Trop Dis, vol. 10, no. 3, 2025, pp. 230-235. https://doi.org/10.18231/j.ijmmtd.2024.040
Chicago
Kshirsagar, D., Thakar, V. H., Dalal, B. A., Babu, A., Modak, M., Kumar, M.. "Candidemia in a tertiary care hospital: Changing trends." IP Int J Med Microbiol Trop Dis 10, no. 3 (2025): 230-235. https://doi.org/10.18231/j.ijmmtd.2024.040